Endpoints News Jan 27, 2026 Insilico’s latest deal is a $120M cardiometabolic drug discovery pact with Qilu Pharma
Endpoints News Jan 21, 2026 Fosun-funded Hygtia Therapeutics licenses Insilico’s NLRP3 inhibitor for Parkinson’s